More than one-third of advanced-melanoma patients given nivolumab in study are alive five years after starting treatment, researchers say
The Washington Post (4/17, Mcginley) reports in “To Your Health” that research indicated “more than a third of advanced-melanoma patients who received one of the new immunotherapy drugs in an early trial are alive five years after starting treatment – double the survival rate typical of the disease.” Investigators found “that 34 percent of patients with metastatic melanoma who received...nivolumab have survived.” The Post points out that “the five-year survival rate for patients with advanced melanoma who got other treatments was 16.6 percent between 2005 and 2011, according to the National Cancer Institute.” The findings were presented at the American Association for Cancer Research annual meeting.
